Relatively frequent mutations in FGFR2 (10% of endometrial cancer) and FGFR3 (20% of urothelial cancer), gene fusion in FGFR2 (45% of intrahepatic cholangiocarcioma) and gene amplification in FGFR1 (19% of ER-positive breast and 17% of squamous cell lung cancer) and FGFR2 (< 10% of gastric cancer) have been described [20]. Here, FGFR2 is linked to endometrial cancer.